Forward Pharma A/S (NASDAQ: FWP) has recently received a number of price target changes and ratings updates:

  • 10/6/2017 – Forward Pharma A/S was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/30/2017 – Forward Pharma A/S was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 9/27/2017 – Forward Pharma A/S had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $6.00 price target on the stock, up previously from $5.00.
  • 9/21/2017 – Forward Pharma A/S was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/12/2017 – Forward Pharma A/S was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/30/2017 – Forward Pharma A/S was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Forward Pharma A/S (NASDAQ:FWP) opened at 6.71 on Wednesday. Forward Pharma A/S has a 52-week low of $5.20 and a 52-week high of $33.00. The firm’s 50-day moving average price is $14.35 and its 200 day moving average price is $19.40.

The company also recently declared an annual dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, September 7th were paid a $22.903 dividend. The ex-dividend date was Wednesday, September 6th. Forward Pharma A/S’s payout ratio is currently -3,249.25%.

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.